"We’re in this with you, to help you get the care you need, safely. Vanderbilt Health has restarted surgeries, procedures and clinic visits that were paused or delayed. Safety is our top priority, with measures that follow – and in some cases exceed – local, state and CDC public health recommendations. Everyone wears a mask – patients, visitors, doctors, nurses and staff. We’re sanitizing rooms between each patient, and cleaning public spaces frequently throughout the day. We’re checking everyone for fever and symptoms before they enter our facilities. We’ve spaced chairs in waiting areas, limited the number who can ride elevators at once and made other changes so we can keep a safe (6 feet) physical distance."

During the past decade, Vanderbilt Eye Institute conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 3 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Vanderbilt Eye Institute" #1 sponsor was "Vanderbilt University" with 6 trials, followed by "Pfizer" with 3 trials sponsored, "Jaeb Center for Health Research" with 2 trials sponsored, "Vanderbilt University Medical Center" with 2 trials sponsored and "Allergan" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Vanderbilt Eye Institute" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "National Institutes of Health (NIH)" with 2 trials as a collaborator, "Pediatric Eye Disease Investigator Group" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Glaucoma Research Society of Canada" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Vanderbilt Eye Institute" are "Glaucoma" (4 trials), "Age-related Macular Degeneration" (2 trials), "Amblyopia" (2 trials), "Inflammation" (2 trials) and "Advanced Malignancies Except Leukemia" (1 trials). Many other conditions were trialed in "Vanderbilt Eye Institute" in a lesser frequency.

Most popular intervention types in "Vanderbilt Eye Institute" are "Drug" (12 trials), "Other" (8 trials), "Device" (4 trials), "Procedure" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "0.67% Sodium Chloride Ophthalmic Solution" (1 trials), "5-Fluorouracil" (1 trials), "Acuvail" (1 trials) and "Ahmed FP7 Valve" (1 trials). Other intervention names were less common.

The vast majority of trials in "Vanderbilt Eye Institute" are 26 trials for "All" genders.

Currently, there are NaN active trials in "Vanderbilt Eye Institute". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 15 completed trials in Vanderbilt Eye Institute, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Vanderbilt Eye Institute, 3 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".